This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Pennant Group, Inc. (PNTG) Misses Q1 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -13.33% and 3.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Market: Microsoft, Novo Nordisk, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
New Strong Buy Stocks for April 17th
by Zacks Equity Research
IOT, PNTG, ACLX, ELUXY and AB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Why Fast-paced Mover The Pennant Group, Inc. (PNTG) Is a Great Choice for Value Investors
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
PNTG vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
3 Medical Device Stocks With Potential to Fight Recession Risk
by Indrajit Bandyopadhyay
Increasing interest rates, higher costs and rising unemployment paint an unfavorable picture with the risk of a recession looming large. Here we discuss three medical stocks that may be good bets even in a recession.
HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza
by Zacks Equity Research
HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.
Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group
by Zacks Equity Research
Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.
4 Promising Stocks From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.
Select Medical (SEM) Forays Into Indiana With Lutheran Health JV
by Zacks Equity Research
Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.
PNTG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Ensign Group's (ENSG) Buyout Consolidates Colorado Presence
by Zacks Equity Research
The Ensign Group (ENSG) buys two skilled nursing facilities in Colorado, aiming to expand its portfolio of nursing homes in the state.
Despite Fast-paced Momentum, The Pennant Group, Inc. (PNTG) Is Still a Bargain Stock
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
PNTG vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
The Pennant Group, Inc. (PNTG) Matches Q4 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 0% and 6.01%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 3.53% and 1.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant
by Zacks Equity Research
Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry
by Zacks Equity Research
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.
PNTG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Are Investors Undervaluing The Pennant Group (PNTG) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PNTG vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
The Pennant Group, Inc. (PNTG) Q3 Earnings Lag Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -22.22% and 2.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PNTG vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Wall Street Analysts Believe The Pennant Group, Inc. (PNTG) Could Rally 44%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 43.5% upside potential for The Pennant Group, Inc. (PNTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Pennant Group, Inc. (PNTG) Meets Q2 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 0% and 2.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?